[A18-28] Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 01.08.2018
Project no.:
A18-28
Commission:
Commission awarded on 02.05.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
bDMARD-naive adults with moderate to severe active rheumatoid arthritis for whom a first treatment with a bDMARD is indicated
Negative effect in serious infections; indication of lesser benefit in comparison with the comparator therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A18-56 | Tofacitinib (rheumatoid arthritis) - Addendum to Commission A18-28 | Commission completed |
| A18-52 | Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-51 | Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-18 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-165 | Tofacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-121 | Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-115 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |